4.4 Article

Benzodiazepine Use in Breast Cancer Survivors: Findings from a Consecutive Series of 1,000 Patients

Journal

ONCOLOGY
Volume 81, Issue 1, Pages 9-11

Publisher

KARGER
DOI: 10.1159/000330814

Keywords

Anxiety; Cancer survivors; Benzodiazepine; Breast cancer

Categories

Funding

  1. [K24CA131099]
  2. NATIONAL CANCER INSTITUTE [K24CA131099] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Objective: This study reports the percentage of breast cancer survivors receiving ongoing benzodiazepines and the circumstances surrounding their usage. Methods: The medical records of 1,000 consecutive breast cancer survivors who were no longer receiving adjuvant chemotherapy were reviewed. Results: Among those patients, 7.9% (95% confidence interval 6.2-9.6; higher than the 3% rate in the general population) were receiving benzodiazepines. Lorazepam was most commonly prescribed. Sixty-eight patients were cancer free at their last visit, and 51 had not been taking benzodiazepines prior to their cancer diagnosis. Anxiety was the single most frequent reason for initiating and continuing benzodiazepines. Conclusion: Anxiety appears to be a common explanation for relatively high rates of benzodiazepine use in breast cancer survivors. This finding merits further study. Copyright (C) 2011 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available